In the DESTINY-Gastric01 trial (NCT03329690), T-DXd 6·4 mg/kg demonstrated significant clinical benefit in patients from Japan or the Republic of Korea with HER2+ locally advanced or metastatic gastric or GEJ adenocarcinoma that had progressed after at least two prior lines of therapy.14 Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.